Mizuho Markets Americas LLC Takes Position in Charles River Laboratories International, Inc. $CRL

Mizuho Markets Americas LLC bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 170,000 shares of the medical research company’s stock, valued at approximately $26,598,000. Mizuho Markets Americas LLC owned about 0.35% of Charles River Laboratories International at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in CRL. Cromwell Holdings LLC increased its stake in shares of Charles River Laboratories International by 542.9% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock worth $27,000 after acquiring an additional 152 shares during the period. Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International during the 2nd quarter worth about $29,000. Geneos Wealth Management Inc. lifted its holdings in shares of Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares during the period. Allworth Financial LP increased its holdings in shares of Charles River Laboratories International by 172.7% during the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 190 shares in the last quarter. Finally, SJS Investment Consulting Inc. acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $48,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, December 15th. Morgan Stanley set a $185.00 target price on shares of Charles River Laboratories International in a research report on Monday, December 1st. Robert W. Baird set a $224.00 price objective on Charles River Laboratories International in a report on Friday, January 9th. Wall Street Zen raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Sunday, December 21st. Finally, Citigroup raised their price objective on Charles River Laboratories International from $200.00 to $265.00 and gave the company a “buy” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $209.46.

Charles River Laboratories International Price Performance

CRL stock opened at $219.81 on Monday. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $228.88. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The stock has a market cap of $10.82 billion, a price-to-earnings ratio of -140.90, a price-to-earnings-growth ratio of 6.57 and a beta of 1.61. The business has a fifty day moving average of $191.81 and a two-hundred day moving average of $174.26.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The company’s revenue was down .5% compared to the same quarter last year. During the same period in the prior year, the business posted $2.59 EPS. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.